Anglican: Obtained the Drug Registration Certificate for Sodium Bicarbonate Tablets

Anglicon announced that the company recently received a Drug Registration Certificate for Carbonated Sevelamer Tablets issued by the National Medical Products Administration. The drug approval number is valid until March 2, 2031, with a dosage specification of 0.8g. This drug is used to control hyperphosphatemia in adult patients with chronic kidney disease, and obtaining this certificate is equivalent to passing consistency evaluation. This will help supplement and enrich the company's product pipeline in the field of kidney disease, enhancing market competitiveness. However, drug sales are subject to factors such as policies and market conditions, so there is uncertainty in specific circumstances.